Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.

Author
:
MJ Levin
A Ustianowski
S De Wit
O Launay
M Avila
A Templeton
Y Yuan
S Seegobin
A Ellery
DJ Levinson
P Ambery
RH Arends
R Beavon
K Dey
P Garbes
EJ Kelly
GCKW Koh
KA Near
KW Padilla
K Psachoulia
A Sharbaugh
K Streicher
MN Pangalos
MT Esser
Group. Study
Abstract
:

The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days.
Year of Publication
:
2022
Journal
:
The New England journal of medicine
Volume
:
386
Issue
:
23
Number of Pages
:
2188-2200
Date Published
:
2022
ISSN Number
:
0028-4793
URL
:
https://www.nejm.org/doi/10.1056/NEJMoa2116620?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
DOI
:
10.1056/NEJMoa2116620
Short Title
:
N Engl J Med
Download citation